One-year Follow-up Results of the Optimal Thromboprophylaxis in Elderly Chinese Patients with Atrial Fibrillation (ChiOTEAF) registry

被引:8
作者
Guo, Yutao [1 ,2 ,3 ]
Wang, Hao [4 ]
Kotalczyk, Agnieszka [2 ,3 ,5 ]
Wang, Yutang [4 ]
Lip, Gregory Y. H. [1 ,2 ,3 ,6 ]
机构
[1] Chinese Peoples Liberat Army Gen Hosp, Med Ctr 6, Dept Pulm Vessel & Thrombot Dis, Beijing, Peoples R China
[2] Univ Liverpool, Liverpool Ctr Cardiovasc Sci, Liverpool, Merseyside, England
[3] Liverpool Heart & Chest Hosp, Liverpool, Merseyside, England
[4] Chinese Peoples Liberat Army Gen Hosp, Med Ctr 2, Dept Cardiol, Beijing, Peoples R China
[5] Med Univ Silesia, Silesian Ctr Heart Dis, Dept Cardiol Congenital Heart Dis & Electrotherap, Zabrze, Poland
[6] Aalborg Univ, Dept Clin Med, Aalborg Thrombosis Res Unit, Aalborg, Denmark
基金
北京市自然科学基金;
关键词
atrial fibrillation; mortality; prognosis; registry; stroke prevention; thromboprophylaxis; ANTAGONIST ORAL ANTICOAGULANTS; ANTITHROMBOTIC TREATMENT; STROKE PREVENTION; EUROPEAN-SOCIETY; ASIAN PATIENTS; GLOBAL BURDEN; EPIDEMIOLOGY; POPULATION; MANAGEMENT; WARFARIN;
D O I
10.1002/joa3.12608
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: The high prevalence of atrial fibrillation (AF) in the very elderly population (aged >80 years) might be underestimated. The elderly are at increased risk of both fatal stroke and bleeding. The Optimal Thromboprophylaxis in Elderly Chinese Patients with Atrial Fibrillation (ChiOTEAF) registry provides contemporary management strategies among the elderly Chinese patients in the new era of non-vitamin K antagonists. Objective: To present the 1-year follow-up data from the ChiOTEAF registry, focusing on the use of antithrombotic therapy, rate vs. rhythm control strategies, and determinants of mortality and stroke. Methods: The ChiOTEAF registry analyzed consecutive AF patients presenting in 44 centers from 20 Chinese provinces from October 2014 to December 2018. Endpoints of interest were mortality, thromboembolism, major bleedings, cardiovascular comorbidities, and hospital re-admissions. Results: Of the 7077 patients enrolled at baseline, 657 patients (9.3%) were lost to the follow-up and 435 deaths (6.8%) occurred. The overall use of anticoagulants remains low, approximately 38% of the entire cohort at follow-up, with similar proportions of vitamin K antagonists (VKA) and non-vitamin K antagonists (NOACs). Antiplatelet therapy was used in 38% of the entire cohort at follow-up, and more commonly among high-risk patients (41%). Among those on a NOAC at baseline, 22.4% switched to antiplatelet therapy alone after one year. Independent predictors of stroke/transient ischemic attack/peripheral embolism and/or mortality were age, heart failure, chronic kidney disease, prior ischemic stroke, dementia, and chronic obstructive pulmonary disease. Conclusions: The ChiOTEAF registry provides contemporary data on AF management, including stroke prevention. The poor adherence of NOACs and common use of antiplatelet in these high-risk elderly population calls for multiple comorbidities management.
引用
收藏
页码:1227 / 1239
页数:13
相关论文
共 50 条
  • [31] Follow-up of atrial fibrillation: The initial experience of the Canadian registry of atrial fibrillation
    Kerr, C
    Boone, J
    Connolly, S
    Greene, M
    Klein, G
    Sheldon, R
    Talajic, M
    EUROPEAN HEART JOURNAL, 1996, 17 : 48 - 51
  • [32] One-year follow-up after pulmonary vein isolation using a single mesh catheter in patients with paroxysmal atrial fibrillation
    Steinwender, Clemens
    Hoenig, Simon
    Leisch, Franz
    Hofmann, Robert
    HEART RHYTHM, 2010, 7 (03) : 333 - 339
  • [33] Cryoballoon ablation in Chinese patients with paroxysmal atrial fibrillation: 1-year follow-up
    Ling, Tian-You
    Jin, Qi
    Pan, Wen-Qi
    Zhang, Ning
    Lin, Chang-Jian
    Lee, Hon-Chi
    Wu, Li-Qun
    PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY, 2017, 40 (10): : 1067 - 1072
  • [34] Analysis of one-year follow-up results and treatment costs of patients with PTE in a tertiary care center
    Ergul, Ersin
    Ucar, Elif Yilmazel
    Araz, Omer
    Aksakal, Alperen
    Kerget, Bugra
    Saglam, Leyla
    TUBERKULOZ VE TORAKS-TUBERCULOSIS AND THORAX, 2023, 71 (04): : 390 - 399
  • [35] A prospective 5-year follow-up after population-based systematic screening for atrial fibrillation
    Engdahl, Johan
    Holmen, Anders
    Rosenqvist, Marten
    Stromberg, Ulf
    EUROPACE, 2018, 20 : F306 - F311
  • [36] Incidence and predictors of hospitalization in patients with atrial fibrillation: results from the Chinese atrial fibrillation registry study
    Dong, Zhaojie
    Du, Xin
    Lu, Shangxin
    Jiang, Chao
    Xia, Shijun
    He, Liu
    Su, Xin
    Jia, Zhaoxu
    Long, Deyong
    Sang, Caihua
    Tang, Ribo
    Liu, Nian
    Bai, Rong
    Yu, Ronghui
    Dong, Jianzeng
    Ma, Changsheng
    BMC CARDIOVASCULAR DISORDERS, 2021, 21 (01)
  • [37] Contact force mapping during catheter ablation for atrial fibrillation: procedural data and one-year follow-up
    Wutzler, Alexander
    Huemer, Martin
    Parwani, Abdul Shokor
    Blaschke, Florian
    Haverkamp, Wilhelm
    Boldt, Leif-Hendrik
    ARCHIVES OF MEDICAL SCIENCE, 2014, 10 (02) : 266 - 272
  • [38] Mortality and functional status at one-year of follow-up in elderly patients with prolonged ICU stay
    Pintado, M. C.
    Villa, P.
    Lujan, J.
    Trascasa, M.
    Molina, R.
    Gonzalez-Garcia, N.
    de Pablo, R.
    MEDICINA INTENSIVA, 2016, 40 (05) : 289 - 297
  • [39] Nutritional Risk and Mortality at One Year for Elderly Patients Hospitalized with Nonvalvular Atrial Fibrillation. NONAVASC Registry
    Arenas Miquelez, A.
    Requena Calleja, M. A.
    Gullon, A.
    Pose Reino, A.
    Formiga, F.
    Camafort, M.
    Cepeda Rodrigo, J. M.
    Mostaza, J. M.
    Suarez Fernandez, C.
    Diez-Manglano, Jesus
    JOURNAL OF NUTRITION HEALTH & AGING, 2020, 24 (09) : 981 - 986
  • [40] Middle East Treatment Strategies and Clinical Outcomes in Patients with Atrial Fibrillation: One-Year Follow-up Data from Garfield-AF Study
    Begum Yetis Sayin
    Wael Al Mahmeed
    Hany Ibrahim Ragy
    Atef Elbahry
    Saverio Virdone
    Ajay K. Kakkar
    Murat Ersanlı
    Ali Oto
    Advances in Therapy, 2021, 38 : 2391 - 2405